Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cinolazepam→

Cinolazepam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
75696-02-5
Molecular formula
C18H13ClFN3O2
Molecular weight
357.8 g/mol
Drug class
Benzodiazepine hypnoticpositive allosteric modulator of GABAA receptors
Mechanism of action
Enhances GABA-mediated inhibitory neurotransmission through positive allosteric modulation of GABAA receptor complexes at the benzodiazepine binding site, producing sedative and hypnotic effects.
Indications / reported uses
  • Short-term treatment of insomnia in countries where cinolazepam is authorised; use is limited by sedation, tolerance, dependence and withdrawal risk

Sources: NLM MeSH — Cinolazepam · PubMed — Cinolazepam benzodiazepine hypnotic · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cinolazepam Environmental Risk Assessment (ERA) (the Cinolazepam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.